The funds may launch a 1.5 billion euros IPO for an enterprise value of 10-12 billion
Stada, a German pharma company that belongs to Bain Capital and Cinven, the owner of the cold medicine Grippostad, sun cream Ladival and cough syrup Silomat, is working on an IPO on Frankfurt Market, Reuters reported. If the market conditions will remain positive, the firm may release a statement about the listing worth in the region of 1.5 billion euros on the ground of an enterprise value of 10-12 billion.
Bloomberg previously reported that Stada attracted the interest of Clayton Dubilier & Rice and later of GTCR, but a sale did not concretize.
Bain and Cinven acquired the asset in 2017 through a delisiting worth 5.3 billion (press release).
In 1H24, Stada has sales of 2.02 billion (+9%), an ebitda of 463.5 million (+11%) (press release), while in 2023 it psted a 3.73 billion turnover and an ebitda of 802 million (press release).
